Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor

International Journal of Pharmaceutics

Volumn 258, Issue 1-2, 2003, Pages 11-19

  Li, Hong ^a   Song, Jong Hwa ^a   Park, Jeong Sook ^a   Han, Kun ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Caco 2; DPPC; Liposome; Oral delivery; PEG coated; rhEGF

Indexed keywords

GAMMA UROGASTRONE; LIPOSOME; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH ULCER;

EID: 0037500855     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00158-3     Document Type: Article

References (26)

1. Anderson K.E., Stevenson B.R., Rogers J.A. Folic acid-PEO-labeled liposomes to improve gastrointestinal absorption of encapsulated agents. J. Control. Release. 60:1999;189-198.
2. Anderson K.E., Eliot L.A., Stevenson B.R., Rogers J.A. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form. Pharm. Res. 18:2001;316-322.
3. Annaert P., Kinget R., Naesens L., Clercq E.D., Augustijins P. Transport, uptake and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:1997;492-496.
4. Bangham A.D., Hill H.W., Miller N.G.A. Preparation and use of liposomes as models of biological membranes. J. Methods Membr. Biol. 1:1974;1-68.
5. Bower J.M., Camble R., Gregory H., Gerring E.L., Willshire I.R. The inhibition of gastric acid secretion by epithelial growth factor. Experientia. 31:1975;825-826.
6. Bruce J.A., Susanna P. Metabolism of a neurotensin (8-13) analog by intestinal and nasal enzymes and approaches to stabilize this peptide at these absorption sites. Int. J. Pharm. 117:1995;95-100.
7. Carpenter G., Cohen S. Epidermal growth factor (EGF). Annu. Rev. Biochem. 48:1979;193-216.
8. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13:1996;1838-1845.
9. Elder J.B., Ganguli P.C., Gillespie I.E., Gerring E.L., Gregory H. Effect of urogastrone on gastrin secretion and plasma gastrin levels in normal subjects. Gut. 16:1975;887-893.
10. Gregory H. Isolation and structure of urogastrone and its relationship to EGF. Nature. 257:1975;325-327.
11. Han K., Choi M.S., Chung Y.B. Site-specific degradation and transport of recombinant human epidermal growth factor (rhEGF) in the rat gastrointestinal mucosa. Int. J. Pharm. 168:1998a;189-197.
12. Han K., Lee S.J., Kim J.H., Chung Y.B. Oral bioadhesive gels of rhEGF for the healing of gastric ulcers. J. Korean Pharm. Sci. 28:1998;99-107.
13. Hovgaard L., Brondsted H., Nielsen H.M. Drug delivery studies in Caco-2 monolayers. 2. Absorption enhancer effects of lysophophatidylcholines. Int. J. Pharm. 114:1995;141-149.
14. Iwanaga K., Ono S., Narioka K., Morimoto K., Kakemi M., Yamashita S., Nango M., Oku N. Oral delivery of insulin by using surface coating liposomes improvement of stability of insulin in GI tract. Int. J. Pharm. 157:1997;73-80.
15. Iwanaga K., Ono S., Narioka K., Kakemi M., Morimoto K., Yamashita S., Namba Y., Oku N. Application of surface-coated liposomes for oral delivery of peptide: effect of coating the liposome's surface on the GI transit of insulin. J. Pharm. Sci. 88:1999;248-252.
16. Jenkins P.G., Howard K.A., Blackhall N.W., Thomas N.W., Davis S.S., O'hagan D.T. Microparticulate absorption from the rat intestine. J. Control. Release. 29:1994;339-350.
17. Kim A., Yun M.O., Oh Y.K., Ahn W.S., Kim C.K. Pharmacodynamics of insulin in polyethylene glycol-coated liposomes. Int. J. Pharm. 180:1999;75-81.
18. Kirkegaard P., Olsen P.S., Poulsen S.S., Nexo E. Epidermal growth factor inhibits cysteamine-induced duodenal ulcer. Gestroenterology. 85:1983;1277-1283.
19. Konturek S.J., Brzozowski T., Piastucki I. Role of mucosal prostaglandins and DNA synthesis in gastric cytoprotection by luminal epidermal growth factor. Gut. 22:1981a;927-932.
20. Konturek S.J., Radecki T., Brzozowski T. Gastric cytoprotection by epidermal growth factor. Gestroenterology. 81:1981;438-443.
21. Moribe K., Tanaka E., Maruyama K., Iwatsuru M. Enhanced encapsulation of amphotericin B into liposoms by complex formation with polyethylene glycol derivatives. Pharm. Res. 15:1998;1737-1742.
22. Moribe K., Maruyama K., Iwatsuru M. Encapsulation characteristics of nystatin in liposomes: effect of cholesterol and polyethylene glycol derivatives. Int. J. Pharm. 188:1999;193-202.
23. 2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16:1993;68-73.
24. Senderoff R.I., Wootton S.C., Boctor A.M., Chen T.M., Giordani A.B., Julian T.N., Radebaugh G.W. Aqueous stability of human epidermal growth factor. Pharm. Res. 11:1994;1-48.
25. Sheng H.B., Shah P.K., Audus K.L. Demonstration of sucralfate-mediated preservation of growth factor bioactivity in the presence of low pH with a human gastric epithelial cell line (AGS). Pharm. Res. 13:1996;1122-1126.
26. Takeuchi H., Yamamoto H., Kawashima Y. Mucoadhesive nanoparticulates systems for peptide drug delivery. Adv. Drug Deliv. Rev. 47:2001;39-54.